Tarsus Pharmaceuticals (TARS) Other Non-Current Assets (2019 - 2026)

Tarsus Pharmaceuticals' Other Non-Current Assets history runs 8 years deep, the most recent figure standing at $2.0 million for Q1 2026.

• On a quarterly basis, Other Non-Current Assets fell 21.93% year-over-year to $2.0 million in Q1 2026; TTM through Mar 2026 was $2.0 million, a 21.93% decrease from a year earlier, with the FY2025 full-year figure at $1.9 million, down 27.36% from the prior year.
• Other Non-Current Assets rose to $2.0 million in Q1 2026 per TARS's latest filing, from $1.9 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $2.6 million in Q1 2025 and bottomed at $529000.0 in Q1 2023.
• The 5-year median for Other Non-Current Assets is $1.2 million (2025), against an average of $1.3 million.
• Across the five-year window, Other Non-Current Assets slumped 63.9% in 2022 and soared 158.8% in 2023, its largest moves.
• Year by year, Other Non-Current Assets stood at $585000.0 in 2022, then soared by 158.8% to $1.5 million in 2023, then jumped by 69.22% to $2.6 million in 2024, then declined by 27.36% to $1.9 million in 2025, then advanced by 7.52% to $2.0 million in 2026.
• Per Business Quant, the three latest TARS Other Non-Current Assets figures stand at $2.0 million (Q1 2026), $1.9 million (Q4 2025), and $1.2 million (Q3 2025).